Original language | English |
---|---|
Pages (from-to) | 11-14 |
Number of pages | 4 |
Journal | Papillomavirus Research |
Volume | 6 |
DOIs | |
State | Published - Dec 2018 |
Externally published | Yes |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Papillomavirus Research, Vol. 6, 12.2018, p. 11-14.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men
AU - Ellsworth, G. B.
AU - Lensing, S. Y.
AU - Ogilvie, C. B.
AU - Lee, J. Y.
AU - Goldstone, S. E.
AU - Berry-Lawhorn, J. M.
AU - Jay, N.
AU - Stier, E. A.
AU - Logan, J. S.
AU - Einstein, M. H.
AU - Saah, A.
AU - Mitsuyasu, R. T.
AU - Aboulafia, D.
AU - Palefsky, J. M.
AU - Wilkin, T. J.
N1 - Funding Information: National Institutes of Health [K23 AI 55038 to T.J.W., UL1 RR024996 to Weill Cornell Clinical and Translational Science Center, U01 CA121947–01 to R.T.M., M01-RR00865 to Weill Cornell Clinical and Translational Science Center, T32 AI007613 to Division of Infectious Diseases of Weill Cornell Medical College, and UL1 RR024131 to University of California at San Francisco Clinical and Translational Science Institute]. Merck Laboratories provided funding for the HPV antibody assays and provided the vaccine doses for this study. Funding Information: Mark H. Einstein has advised or participated in educational speaking activities but not received an honorarium from Merck; Montefiore Medical Center had received payment for time spent by M.H.E. for these activities; Montefiore Medical Center has received grant funding from Merck for research-related costs of clinical trials for which M.H.E. was primary investigator. Alfred Saah is an employee of Merck Laboratories and owns stock in Merck Laboratories. Joel M. Palefsky has served as a consultant for Merck; University of California at San Francisco has received grant funding from Merck for advisory board activities of J.M.P. and for research-related costs of clinical trials for which J.M.P. was the primary investigator. Timothy J. Wilkin has served as an ad hoc advisor for GlaxoSmit hKl ine/ViiV Healthcare, and has received grant funding (paid to Weill Cornell Medicine) from GlaxoSmit hKl ine/ViiV Healthcare.
PY - 2018/12
Y1 - 2018/12
UR - http://www.scopus.com/inward/record.url?scp=85048803025&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2018.05.001
DO - 10.1016/j.pvr.2018.05.001
M3 - Article
C2 - 29807211
AN - SCOPUS:85048803025
SN - 2666-6790
VL - 6
SP - 11
EP - 14
JO - Papillomavirus Research
JF - Papillomavirus Research
ER -